Fact Sheet

Early Signal Prediction Platform

Overcome inefficiencies in clinical trial analysis using AI-powered insights

The challenge

Clinical trials in crucial areas like vaccines, oncology and cardiovascular diseases face significant challenges stemming from a fragmented, manual data review process. Data scattered across numerous disconnected systems leads to delays in detecting vital safety and efficacy trends, with current processes taking up to six months to uncover critical insights. This outdated approach slows a trial's progress while increasing the risk of errors and potentially costly delays to market.

The urgency to streamline clinical data analysis arises from the need to quickly identify safety signals and efficacy indicators within massive, complex datasets. For example, early prediction of adverse effects (e.g., accelerated osteoarthritis in patients using a given NSAID) can prevent serious health outcomes and guide timely adjustments to study protocols. Similarly, recognizing the futility of a trial early on can save millions in unnecessary costs and redirect resources to more promising research avenues. Currently, taking over six months to act on such data not only compromises patient safety but also impacts a study's strategic direction.

IQVIA's innovative solution tackles these inefficiencies by drastically reducing the data analysis timeframe from several months to mere weeks. By leveraging advanced AI algorithms and a unified data platform, we streamline the integration and analysis of clinical trial data, enhancing adaptability and decision-making speed.

The solution

Early Signal Prediction with IQVIA

IQVIA's Early Signal Prediction harnesses AI to provide a unified solution that streamlines data integration and complex data analysis from multiple sources. Our innovative platform seamlessly integrates with IQVIA Clinical Data Analytics Solutions (CDAS), leveraging its advanced data management capabilities to provide a secure and compliant environment for all your clinical trial data needs. From the outset of trial planning throughout study duration, our platform continuously monitors data for emergent trends, safety signals or evidence of futility, allowing for timely adjustments to study protocols or intervention strategies.



Key features of Early Signal Prediction

- **Enhanced security and compliance:** Our platform is deeply rooted in a secure and compliant framework, adhering to GxP, GDPR, HIPAA and CFR 21 Part11 standards, ensuring that data integrity and patient privacy are maintained at all times.
- **Streamlined data integration:** Leveraging both descriptive and prescriptive AI, including generative AI and large language models (LLMs), our solution unifies and simplifies the complex analysis of diverse data sources, enhancing the accuracy and efficiency of clinical data interpretation.
- **Proactive trend monitoring:** Our Hypothesis Center generates hypotheses based on historical clinical data, real-world evidence (RWE) and relevant literature, while our Review Center tests these hypotheses on real-time data to predict and review signals. This integrated approach empowers clinical teams to make informed decisions using an interactive user interface that aligns with standard clinical and regulatory guidelines, thereby optimizing trial outcomes and ensuring swift, data-informed responses to emergent trends.

Your benefits

Accelerated time-to-market

Our solution significantly shortens your timeline from discovery to actionable insights, facilitating a faster path to market in a landscape where innovation speed is critical for leadership.

Enhanced regulatory compliance and risk management

Anchored in the secure and compliant environment of IQVIA CDAS, our solution meets and exceeds regulatory standards, minimizing the risk of delays and non-compliance penalties.

Optimized resource allocation

Early Signal Prediction leverages AI-driven insights to identify the most promising research paths early, ensuring efficient and effective allocation of trial resources.

Empowerment of strategic decision-making

Our solution enhances your ability to make rapid, informed decisions on key aspects like study design and safety investigations, vital for maintaining participant safety and ensuring trial success in a fast-paced research environment.

Join us

Built on a foundation of extensive research and investment, our Early Signal Prediction platform offers advanced security, compliance and continuous innovation. As your partner, IQVIA provides more than just a platform — we offer ongoing support and enhancements that evolve with the dynamic demands of clinical trials. This ensures you stay ahead with the latest AI and regulatory standards, making our solution both cutting-edge and thoroughly tested.

Reach out to schedule a consultation about Early Signal Prediction and CDAS.

IQVIA TECHNOLOGIES

CONTACT US

OrchestrateYourTrials@iqvia.com

iqvia.com/CDAS